GEMMA Biotherapeutics is a new therapeutics company established by Dr. Jim Wilson, a gene therapy specialist, and has closed its seed funding at $34 million. This investment will support the company’s clinical-stage gene therapy programs and growth of operations.
Double Point Ventures, Bioluminescence Ventures, Earlybird Venture Capital, and Savanne Life Sciences equally backed the seed funding.
GEMMA Forcing the Pace of Gene Therapy Research
The president and the CEO of the GEMMABio were Dr. Jim Wilson, who thanked the company’s partners. ‘This support reflects common values of enhancing affordable and accessible gene therapies for patients across the world,’ he noted.
Campbell Murray, a Senior Partner at Bioluminescence Ventures, mentioned, “This strategy makes GEMMABio special.” These sources argue about the possibility of generating value for the key stakeholders and providing life-saving treatments.
Partnering and Integrated Development
When GEMMABio was launched on 1st October 2024, its networks already started implementing friendly programs such as affiliating with Fiocruz, which is a major supplier to the Brazil Ministry of Health.
A well-known source of information, spokesman of the early bird venture capital Florent Gros underscored the mission of the GEMMABio company. “It is an honor to partner with them as they seek to transform the experience of patients through more effective treatments.”
